IRON DEFICIENCY ANEMIA AS A RISK FACTOR FOR PLACENTAL INSUFFICIENCY AND PERINATAL COMPLICATIONS

Objective. To evaluate the efficiency of anti-anemia therapy in the prevention of placental insufficiency (PI) in the second trimester of pregnancy. Subjects and methods. The results of prevention and treatment of perinatal complications were analyzed in 40 pregnant women with anemia. The pathogenetically substantiated package of measures at 17-24 weeks of gestation included drug correction of fetoplacental homeostastic disorders in conjunction with anti-anemia treatment. Results. During treatment, Sideral Forte caused a significant (p < 0.001) increase in the level of hemoglobin from 80.3±1.3 to 114.3±1.8g/l and red blood cells from 3.2±0.41012/l to 4.1±0.31012/l. There was a significant rise in serum iron levels (from 12.5±1.5 to 17.4±1.3 μmol/l) and a substantial ferritin increment that is only possible at the least speed of hemoglobin increases. Thus, the assessment of iron depots by serum ferritin concentrations ascertained that the administration of Sideral Forte increased iron stores. The treatment-induced increment in serum ferritin levels tended to exceed from 32.3±1.2 to 34.5±1.5 μg/l. Conclusion. The high frequency of pregnancy complications makes the early diagnosis and prediction of iron deficiency anemia (IDA), its timely and efficient prevention and treatment extremely relevant. The use of Sideral Forte at a dose of one capsule (30 mg of iron) per day for the treatment of IDA in the complex correction of PI allows achievng not only normalization of iron levels and improvement of quality of life in pregnant women, but also a reducton in the incidence of obstetric and perinatal complications.

pregnancy, anemia, placental insufficiency